SCHEMBL4577441

SCHEMBL4577441

CC(Nc1ccccc1S(=O)(=O)O)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 1/20 0.43
ALDH1A1 P00352 2/20 0.43
HTT P42858 1/20 0.42
TTR P02766 1/20 0.42
FABP4 P15090 1/20 0.42
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42
MAPK14 Q16539 1/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NR4A1 P22736 1/20 0.41
CYP1A2 P05177 1/20 0.39
HTR6 P50406 1/20 0.38
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8653117 0.84 HTR6 (0.58) ADAMTS4ALDH1A1HTTLMNASMN1; SMN2
SCHEMBL7512674 0.82 TTR (0.42) ALDH1A1TTRFABP4CCNA2CDK2
SCHEMBL11559398 0.81 TTR (0.40) ALDH1A1TTRFABP4CCNA2CDK2
SCHEMBL4650108 0.78 ALDH1A1 (0.44) ALDH1A1CA1CA2CA9MMP1
SCHEMBL7520305 0.77 HSD17B10 (0.46) ALDH1A1TTRFABP4CCNA2CDK2
SCHEMBL7446867 0.76 SLC1A3 (0.44) ADAMTS4ALDH1A1HTR6MMP1MMP2
SCHEMBL5062929 0.75 RAB9A (0.52) ALDH1A1HTTLMNASMN1; SMN2MMP1
SCHEMBL5323369 0.75 HPGD (0.49) ADAMTS4ALDH1A1HTTLMNASMN1; SMN2
SCHEMBL7200135 0.75 RAB9A (0.52) ALDH1A1HTTLMNASMN1; SMN2MMP1
SCHEMBL5323373 0.75 HPGD (0.49) ADAMTS4ALDH1A1HTTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020082057-A1 INTERLEUKIN-10 POLYPEPTIDE CONJUGATES, DIMERS THEREOF, AND THEIR USES AMBRX, INC. (US) 2020-04-23 WO claimed
US-9763978-B2 Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) 2017-09-19 US disclosed
US-20150064131-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMERIC BINDERS WITH NON-HYDROLYSABLE COVALENT BONDS AND THEIR USE IN TREATING CELIAC DISEASE VALORISATION-RECHERCHE LIMITED PARTNERSHIP (CA) 2015-03-05 US disclosed
US-8883133-B2 Pharmaceutical compositions comprising polymeric binders with non-hydrolysable their use in treating celiac disease VALORISATION-RECHERCHE LIMITED PARTNERSHIP (CA) 2014-11-11 US disclosed
US-8784792-B2 Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease Valorization-Recherche Limited Partnership (CA) 2014-07-22 US disclosed
US-20120244105-A1 Pharmaceutical Compositions Comprising Polymeric Binders with Non-Hydrolysable Covalent Bonds and Their Use in Treating Celiac Disease VALORISATION-RECHERCHE LIMITED PARTNERSHIP (CA) 2012-09-27 US disclosed
US-20080254099-A1 Such as high molecular weight copolymer of hydroxyethyl methacrylate and 4-styrene sulfonic acid sodium salt; decreasing interaction of gluten or peptide degradation products with intestinal tract; breads VALORISATION-RECHERCHE, LIMITED (CA) 2008-10-16 US disclosed
EP-1948201-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMERIC BINDERS WITH NON-HYDROLYSABLE COVALENT BONDS AND THEIR USE IN TREATING CELIAC DISEASE UNIVERSITE DE MONTREAL (CA) 2008-07-30 EP disclosed
WO-2007053935-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMERIC BINDERS WITH NON-HYDROLYSABLE COVALENT BONDS AND THEIR USE IN TREATING CELIAC DISEASE UNIVERSITE DE MONTREAL (CA) 2007-05-18 WO disclosed